People living with the lung condition bronchiectasis can expect three new treatments to become available in the next ten years, according to GlobalData. However, the leading data and analytics company notes that, while there is great enthusiasm amid key opinion leaders (KOLs) around the new therapies’ innovative approach, patients will still have to take several medications daily to combat the disease.

GlobalData’s latest report, ‘Bronchiectasis Market Size and Trend Report, 2021-2031’, reveals that the launch of the three drugs, combined with the high polypharmacy, is expected to drive the bronchiectasis market to grow from $408.2 million in 2021 to $965.8 million in 2031 in the three major markets (3MM*). Together these products are expected to contribute $457.2 million to the market in the 3MM by 2031.

Ramla Salad, Healthcare Analyst at GlobalData, comments: “KOLs interviewed by GlobalData have shown great enthusiasm for AstraZeneca’s Fasenra, Insmed’s brensocatib and Novartis’s icenticaftor, which are all competing to become the first disease-modifying therapy for bronchiectasis—with sales in 2031 forecast to reach $171.2 million, $271.6 million, and $14.4 million, respectively. However, despite these launches, patients will still be expected to continue receiving multiple classes of therapies such as antibiotics and bronchodilators for combined use.

“Polypharmacy is a key driving force in the bronchiectasis market. Inhaled antibiotics in particular are expected to retain a large market share during the forecast period. In 2021, inhaled antibiotics was the market-leading class, with $265.6 million in sales, and is expected to remain the leader with $314.5 million in sales in 2031.”

Bronchiectasis is still a poorly understood disease, which is exemplified by the modest pipeline activity—only three drugs are expected to launch during the forecast period. Moreover, there are some barriers to growth that could limit the uptake of these therapies such as the high annual cost of therapy associated with biologics like Fasenra and the lack of education among physicians and patients regarding the disease’s diagnosis and treatment.

Salad concludes: “Although these barriers will have some impact on growth, overall, the market is expanding, and ample opportunities exist for developers to further improve the bronchiectasis treatment landscape for patients.”

*3MM: US, Germany, and the UK